Efficacy of Opiate Maintenance Therapy and Adjunctive Interventions for Opioid Dependence with Comorbid Cocaine Use Disorders: A Systematic Review and Meta-Analysis of Controlled Clinical Trials

REFERENCES

• Kleber H D, Weiss R D, Anton R F, Jr, George T P, Greenfield S F, Kosten T R, O'Brien C P, , Work Group on Substance Use Disorders; American Psychiatric Association, et al. Steering Committee on Practice Guidelines. Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry 2007; 164(4 Suppl)5–123
   PubMed Web of Science ®Google Scholar
• Farré M, Mas A, Torrens M, Moreno V, Cami J. Retention rate and illicit opioid use during methadone maintenance interventions: A meta-analysis. Drug Alcohol Depend 2002; 65(3)283–290
   PubMed Web of Science ®Google Scholar
• Marsch L A. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: A meta-analysis. Addiction 1998; 93(4)515–532
   PubMed Web of Science ®Google Scholar
• Schwartz R P, Highfield D A, Jaffe J H, Brady J V, Butler C B, Rouse C O, Callaman J M, O'Grady K E, Battjes R J. A randomized controlled trial of interim methadone maintenance. Arch Gen Psychiatry 2006; 63(1)102–109
   PubMed Web of Science ®Google Scholar
• Gronbladh L, Ohlund L S, Gunne L M. Mortality in heroin addiction: Impact of methadone treatment. Acta Psychiatr Scand 1990; 82(3)223–227
   PubMed Web of Science ®Google Scholar
• Kosten T R, Rounsaville B J, Kleber H D. A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped?. Arch Gen Psychiatry 1987; 44(3)281–284
   PubMed Web of Science ®Google Scholar
• Kidorf M, Stitzer M L. Descriptive analysis of cocaine use of methadone patients. Drug Alcohol Depend 1993; 32(3)267–275
   Google Scholar
• Peles E, Schreiber S, Adelson M. Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. Drug Alcohol Depend 2006; 82(3)211–217
   PubMed Web of Science ®Google Scholar
• Condelli W S, Fairbank J A, Dennis M L, Rachal J V. Cocaine use by clients in methadone programs: Significance, scope, and behavioral interventions. J Subst Abuse Treat 1991; 8(4)203–212
   PubMed Web of Science ®Google Scholar
• Meandzija B, O'Connor P G, Fitzgerald B, Rounsaville B J, Kosten T R. HIV infection and cocaine use in methadone maintained and untreated intravenous drug users. Drug Alcohol Depend 1994; 36(2)109–113
   Google Scholar
• Grella C E, Anglin M D, Wugalter S E. Cocaine and crack use and HIV risk behaviors among high-risk methadone maintenance clients. Drug Alcohol Depend 1995; 37(1)15–21
   PubMed Web of Science ®Google Scholar
• Hartel D M, Schoenbaum E E, Selwyn P A, Kline J, Davenny K, Klein R S, Friedland G H. Heroin use during methadone maintenance treatment: The importance of methadone dose and cocaine use. Am J Public Health 1995; 85(1)83–88
   PubMed Web of Science ®Google Scholar
• Kosten T R, Rounsaville B J, Kleber H D. Antecedents and consequences of cocaine abuse among opioid addicts. A 2.5-year follow-up. J Nerv Ment Dis 1988; 176(3)176–181
   PubMedGoogle Scholar
• Bux D A, Lamb R J, Iguchi M Y. Cocaine use and HIV risk behavior in methadone maintenance patients. Drug Alcohol Depend 1995; 37(1)29–35
   PubMed Web of Science ®Google Scholar
• Leri F, Bruneau J, Stewart J. Understanding polydrug use: Review of heroin and cocaine co-use. Addiction 2003; 98(1)7–22
   PubMed Web of Science ®Google Scholar
• Kenna G A, Nielsen D M, Mello P, Schiesl A, Swift R M. Pharmacotherapy of dual substance abuse and dependence. CNS Drugs 2007; 21(3)213–237
   PubMed Web of Science ®Google Scholar
• Jadad A R, Moore R A, Carroll D, Jenkinson C, Reynolds D J, Gavaghan D J, McQuay H J. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials 1996; 17(1)1–12
   PubMedGoogle Scholar
• Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008], J PT Higgins, S Green. The Cochrane Collaboration. 2008, Accessed on April 1st 2008 from Available at www.cochrane-handbook.org
   Google Scholar
• Review Manager (RevMan) [Computer program]. Version| 5.0. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen 2008
   Google Scholar
• Higgins J PT, Thompson S G. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002; 21(11)1539–1558
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109)629–634
   PubMed Web of Science ®Google Scholar
• Epidat 3.1. Software for epidemiologic analysis of tabulated data. Version 3.1, Accessed on April 1st 2008 from Available at: http://dxsp.sergas.es/ApliEdatos/Epidat/gal/3.6_Descarga.asp?Idioma=En
   Google Scholar
• Arndt I O, Dorozynsky L, Woody G E, McLellan A T, O'Brien C P. Desipramine treatment of cocaine dependence in methadone-maintained patients. Arch Gen Psychiatry 1992; 49(11)888–893
   PubMed Web of Science ®Google Scholar
• Avants S K, Margolin A, Chang P, Kosten T R, Birch S. Acupuncture for the treatment of cocaine addiction. Investigation of a needle puncture control. J Subst Abuse Treat 1995; 12(3)195–205
   PubMedGoogle Scholar
• Avants S K, Margolin A, Holford T R, Kosten T R. A randomized controlled trial of auricular acupuncture for cocaine dependence. Arch Intern Med 2000; 160(15)2305–2312
   PubMedGoogle Scholar
• Downey K K, Helmus T C, Schuster C R. Treatment of heroin-dependent poly-drug abusers with contingency management and buprenorphine maintenance. Exp Clin Psychopharmacol 2000; 8(2)176–84
   PubMed Web of Science ®Google Scholar
• Epstein D H, Hawkins W E, Covi L, Umbricht A, Preston K L. Cognitive-behavioral therapy plus contingency management for cocaine use: Findings during treatment and across 12-month follow-up. Psychol Addict Behav 2003; 17(1)73–82
   PubMed Web of Science ®Google Scholar
• George T P, Chawarski M C, Pakes J, Carroll K M, Kosten T R, Schottenfeld R S. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: A preliminary trial. Biol Psychiatry 2000; 47(12)1080–1086
   PubMed Web of Science ®Google Scholar
• Gonzalez G, Sevarino K, Sofuoglu M, Poling J, Oliveto A, Gonsai K, George T P, Kosten T R. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: Results of a randomized pilot study. Addiction 2003; 98(11)1625–1632
   PubMed Web of Science ®Google Scholar
• González G, Desai R, Sofuoglu M, Poling J, Oliveto A, Gonsai K, Kosten T R. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend 2007; 87(1)1–9
   PubMed Web of Science ®Google Scholar
• Grabowski J, Rhoades H, Elk R, Schmitz J, Davis C, Creson D, Kirby K. Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: Two placebo-controlled double-blind trials. J Clin Psychopharmacol 1995; 15(3)163–174
   PubMed Web of Science ®Google Scholar
• Grabowski J, Rhoades H, Stotts A, Cowan K, Kopecky C, Dougherty A, Moeller F G, Hassan S, Schmitz J. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: Two double-blind randomized clinical trials. Neuropsychopharmacology 2004; 29(5)969–981
   PubMed Web of Science ®Google Scholar
• Handelsman L, Limpitlaw L, Williams D, Schmeidler J, Paris P, Stimmel B. Amantadine does not reduce cocaine use or craving in cocaine-dependent methadone maintenance patients. Drug Alcohol Depend 1995; 39(3)173–180
   PubMed Web of Science ®Google Scholar
• Handelsman L, Rosenblum A, Palij M, Magura S, Foote J, Lovejoy M, Stimmel B. Bromocriptine for cocaine dependence. A controlled clinical trial. Am J Addict 1997; 6(1)54–64
   PubMed Web of Science ®Google Scholar
• Knealing T W, Wong C J, Diemer K N, Hampton J, Silverman K. A randomized controlled trial of the therapeutic workplace for community methadone patients: A partial failure to engage. Exp Clin Psychopharmacol 2006; 14(3)350–360
   Google Scholar
• Kolar A F, Brown B S, Weddington W W, Haertzen C C, Michaelson B S, Jaffe J H. Treatment of cocaine dependence in methadone maintenance clients: A pilot study comparing the efficacy of desipramine and amantadine. Int J Addict 1992; 27(7)849–868
   PubMed Web of Science ®Google Scholar
• Kosten T R, Morgan C M, Falcione J, Schottenfeld R S. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch Gen Psychiatry 1992; 49(11)894–898
   PubMed Web of Science ®Google Scholar
• Kosten T R, Oliveto A, Sevarino K A, Gonsai K, Feingold A. Ketoconazole increases cocaine and opioid use in methadone maintained patients. Drug Alcohol Depend 2002; 66(2)173–180
   Google Scholar
• Kosten T, Oliveto A, Feingold A, Poling J, Sevarino K, McCance-Katz E, Stine S, Gonzalez G, Gonsai K. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend 2003; 70(3)315–325
   PubMed Web of Science ®Google Scholar
• Margolin A, Kosten T R, Avants S K, Wilkins J, Ling W, Beckson M, Arndt I O, Cornish J, Ascher J A, Li S H, et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend 1995; 40(2)125–131
   PubMedGoogle Scholar
• Margolin A, Avants S K, Kosten T R. Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients. Am J Drug Alcohol Abuse 1995; 21(4)469–481
   PubMed Web of Science ®Google Scholar
• Margolin A, Avants S K, Malison R T, Kosten T R. High- and low-dose mazindol for cocaine dependence in methadone- maintained patients: A preliminary valuation. Substance Abuse 1997; 18(3)125–131
   Google Scholar
• Margolin A, Kantak K, Copenhaver M, Avants S K. A preliminary, controlled investigation of magnesium L-aspartate hydrochloride for illicit cocaine and opiate use in methadone-maintained patients. J Addict Dis 2003; 22(2)49–61
   Web of Science ®Google Scholar
• Montoya I D, Gorelick D A, Preston K L, Schroeder J R, Umbricht A, Cheskin L J, Lange W R, Contoreggi C, Johnson R E, Fudala P J. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther 2004; 75(1)34–48
   PubMed Web of Science ®Google Scholar
• Oliveto A H, Feingold A, Schottenfeld R, Jatlow P, Kosten T R. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. Arch Gen Psychiatry 1999; 56(9)812–820
   Google Scholar
• Oliveto A, Poling J, Sevarino K A, Gonsai K R, McCance-Katz E F, Stine S M, Kosten T R. Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients. Drug Alcohol Depend 2005; 79(2)157–65
   Google Scholar
• Petrakis I L, Carroll K M, Nich C, Gordon L T, McCance-Katz E F, Frankforter T, Rounsaville B J. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 2000; 95(2)219–228
   PubMed Web of Science ®Google Scholar
• Petry N M, Martin B. Low-cost contingency management for treating cocaine- and opioid-abusing methadone patients. J Consult Clin Psychol 2002; 70(2)398–405
   PubMed Web of Science ®Google Scholar
• Petry N M, Martin B, Simcic F, Jr. Prize reinforcement contingency management for cocaine dependence: Integration with group therapy in a methadone clinic. J Consult Clin Psychol 2005; 73(2)354–359
   PubMed Web of Science ®Google Scholar
• Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, Martell B, Kosten T R. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 2006; 63(2)219–228
   PubMed Web of Science ®Google Scholar
• Rawson R A, Huber A, McCann M, Shoptaw S, Farabee D, Reiber C, Ling W. A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Arch Gen Psychiatry 2002; 59(9)817–824
   PubMed Web of Science ®Google Scholar
• Reid M S, Angrist B, Baker S A, O'leary S, Stone J, Schwartz M, Leiderman D, Montgomery A, Elkashef A, Majewska D, Robinson J, Rotrosen J. A placebo controlled, double-blind study of mecamylamine treatment for cocaine dependence in patients enrolled in an opiate replacement program. Subst Abus 2005; 26(2)5–14
   Google Scholar
• Rowan-Szal G A, Bartholomew N G, Chatham L R, Simpson D D. A combined cognitive and behavioral intervention for cocaine-using methadone clients. J Psychoactive Drugs 2005; 37(1)75–84
   PubMed Web of Science ®Google Scholar
• Schottenfeld R S, Pakes J R, Oliveto A, Ziedonis D, Kosten T R. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997; 54(8)713–720
   PubMed Web of Science ®Google Scholar
• Schottenfeld R S, Chawarski M C, Pakes J R, Pantalon M V, Carroll K M, Kosten T R. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry 2005; 162(2)340–349
   Google Scholar
• Silverman K, Higgins S T, Brooner R K, Montoya I D, Cone E J, Schuster C R, Preston K L. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch Gen Psychiatry 1996; 53(5)409–415
   PubMed Web of Science ®Google Scholar
• Silverman K, Wong C J, Umbricht-Schneiter A, Montoya I D, Schuster C R, Preston K L. Broad beneficial effects of cocaine abstinence reinforcement among methadone patients. J Consult Clin Psychol 1998; 66(5)811–824
   PubMed Web of Science ®Google Scholar
• Silverman K, Robles E, Mudric T, Bigelow G E, Stitzer M L. A randomized trial of long-term reinforcement of cocaine abstinence in methadone-maintained patients who inject drugs. J Consult Clin Psychol 2004; 72(5)839–854
   PubMed Web of Science ®Google Scholar
• Strain E C, Stitzer M L, Liebson I A, Bigelow G E. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology (Berl) 1994; 116(4)401–406
   PubMed Web of Science ®Google Scholar
• Mattick R, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008, (2):CD002207
   PubMed Web of Science ®Google Scholar
• Foltin R W, Fischman M W. Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans. J Pharmacol Exp Ther 1996; 278(3)1153–1164
   Google Scholar
• Fudala P J, Jaffe J H, Dax E M, Johnson R E. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 1990; 47(4)525–534
   PubMed Web of Science ®Google Scholar
• Kalivas P W, Volkow N D. The Neural Basis of Addiction: A Pathology of Motivation and Choice. Am J Psychiatry 2005; 162(8)1403–1413
   PubMed Web of Science ®Google Scholar
• Caroldi S, De Paris P. Comparative effects of two dithiocarbamates disulfiram and thiram, on adrenal catecholamine content and on plasma dopamine-beta-hydroxylase activity. Arch Toxicol 1995; 69(10)690–693
   PubMed Web of Science ®Google Scholar
• Hoffman B B. Catecholamines, sympaticomimetic drugs and adrenoreceotor antagonists. The Pharmacological Basis of Therapeutics, J. G. Hardman, L. E. Limbird Goodman-Gilman, A. Goodman, Guilman's. McGraw Hill, New York 2001
   Google Scholar
• Castells X, Casas M, Vidal X, Bosch R, Roncero C, Ramos-Quiroga J A, Capellà D. Efficacy of central nervous system stimulant treatment for cocaine dependence: A systematic review and meta-analysis of randomized controlled clinical trials. Addiction 2007; 102(12)1871–1887
   Google Scholar
• Griffith J D, Rowan-Szal G A, Roark R R, Simpson D D. Contingency management in outpatient methadone treatment: A meta-analysis. Drug Alcohol Depend 2000; 58(1–2)55–66
   PubMed Web of Science ®Google Scholar
• Dutra L, Stathopoulou G, Basden S L, Leyro T M, Powers M B, Otto M W. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008; 165(2)179–187
   PubMed Web of Science ®Google Scholar
• Gøtzsche P C, Hróbjartsson A, Maric K, Tendal B. Data extraction errors in meta-analyses that use standardized mean differences. JAMA 2007; 298(4)430–437
   Google Scholar
• Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997; 350(9074)326–329
   PubMed Web of Science ®Google Scholar
• Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep 2007; 9(5)358–364
   PubMedGoogle Scholar
• Nath R P, Upton R A, Everhart E T, Cheung P, Shwonek P, Jones R T, Mendelson J E. Buprenorphine pharmacokinetics: Relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol 1999; 39(6)619–623
   PubMed Web of Science ®Google Scholar
• Sullivan L E, Chawarski M, O'Connor P G, Schottenfeld R S, Fiellin D A. The practice of office-based buprenorphine treatment of opioid dependence: Is it associated with new patients entering into treatment?. Drug Alcohol Depend 2005; 79(1)113–116
   PubMed Web of Science ®Google Scholar
• Karila L, Gorelick D, Weinstein A, Noble F, Benyamina A, Coscas S, Blecha L, Lowenstein W, Martinot J L, Reynaud M, Lépine J P. New treatments for cocaine dependence: A focused review. Int J Neuropsychopharmacol 2008; 11(3)425–438
   PubMed Web of Science ®Google Scholar
• Preti A. New developments in the pharmacotherapy of cocaine abuse. Addict Biol 2007; 12(2)133–151
   Google Scholar